211 related articles for article (PubMed ID: 38245530)
1. Macro CD5L
Lu JC; Wu LL; Sun YN; Huang XY; Gao C; Guo XJ; Zeng HY; Qu XD; Chen Y; Wu D; Pei YZ; Meng XL; Zheng YM; Liang C; Zhang PF; Cai JB; Ding ZB; Yang GH; Ren N; Huang C; Wang XY; Gao Q; Sun QM; Shi YH; Qiu SJ; Ke AW; Shi GM; Zhou J; Sun YD; Fan J
Nat Commun; 2024 Jan; 15(1):621. PubMed ID: 38245530
[TBL] [Abstract][Full Text] [Related]
2. Clinical and biomarker analyses of hepatic arterial infusion chemotherapy plus lenvatinib and PD-1 inhibitor for patients with advanced intrahepatic cholangiocarcinoma.
Huang Y; Du Z; Kan A; He M; Li H; Lai Z; Wen D; Huang L; Li Q; Xu L; Shi M
Front Immunol; 2024; 15():1260191. PubMed ID: 38384459
[TBL] [Abstract][Full Text] [Related]
3. Hepatic arterial infusion of gemcitabine plus oxaliplatin as second-line treatment for locally advanced intrahepatic cholangiocarcinoma: preliminary experience.
Ghiringhelli F; Lorgis V; Vincent J; Ladoire S; Guiu B
Chemotherapy; 2013; 59(5):354-60. PubMed ID: 24821200
[TBL] [Abstract][Full Text] [Related]
4. Lenvatinib Plus Programmed Cell Death Protein-1 Inhibitor Beyond First-Line Systemic Therapy in Refractory Advanced Biliary Tract Cancer: A Real-World Retrospective Study in China.
Shi C; Li Y; Yang C; Qiao L; Tang L; Zheng Y; Chen X; Qian Y; Yang J; Wu D; Xie F
Front Immunol; 2022; 13():946861. PubMed ID: 35967452
[TBL] [Abstract][Full Text] [Related]
5. Significant response to anti-PD-1 based immunotherapy plus lenvatinib for recurrent intrahepatic cholangiocarcinoma with bone metastasis: A case report and literature review.
Chen WX; Li GX; Hu ZN; Zhu P; Zhang BX; Ding ZY
Medicine (Baltimore); 2019 Nov; 98(45):e17832. PubMed ID: 31702638
[TBL] [Abstract][Full Text] [Related]
6. Response to cetuximab and gemcitabine-oxaliplatin in an advanced case of intrahepatic cholangiocarcinoma.
Bralet MP; Bellin MF; Guettier C; Adam R; Paule B
Clin Oncol (R Coll Radiol); 2006 Jun; 18(5):426. PubMed ID: 16817335
[No Abstract] [Full Text] [Related]
7. Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study).
Leone F; Marino D; Cereda S; Filippi R; Belli C; Spadi R; Nasti G; Montano M; Amatu A; Aprile G; Cagnazzo C; Fasola G; Siena S; Ciuffreda L; Reni M; Aglietta M
Cancer; 2016 Feb; 122(4):574-81. PubMed ID: 26540314
[TBL] [Abstract][Full Text] [Related]
8. Conversion therapy for advanced intrahepatic cholangiocarcinoma with lenvatinib and pembrolizumab combined with gemcitabine plus cisplatin: A case report and literature review.
Zhang W; Luo C; Zhang ZY; Zhang BX; Chen XP
Front Immunol; 2022; 13():1079342. PubMed ID: 36700218
[TBL] [Abstract][Full Text] [Related]
9. Durable response with lenvatinib and pembrolizumab combination therapy in a patient with pre-treated metastatic cholangiocarcinoma.
Dreikhausen L; Kusnik A; Schulte N; Eckardt M; Teufel A; Gaiser T; Ebert M; Zhan T
J Gastrointestin Liver Dis; 2021 Sep; 30(3):409-410. PubMed ID: 34551034
[No Abstract] [Full Text] [Related]
10. Case report: A report of the complete pathological response of intrahepatic cholangiocarcinoma after conversion therapy.
Zhang X; Tang H; Fan J; Wang R; Han Y; Su S; Gan Y; Peng F; Rao M; Zhang J; Li B; Yang X
Front Immunol; 2022; 13():1051130. PubMed ID: 36618353
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy for inoperable advanced or metastatic cholangiocarcinoma: retrospective analysis of 78 cases in a single center over four years.
Pracht M; Le Roux G; Sulpice L; Mesbah H; Manfredi S; Audrain O; Boudjema K; Raoul JL; Boucher E
Chemotherapy; 2012; 58(2):134-41. PubMed ID: 22572213
[TBL] [Abstract][Full Text] [Related]
12. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial.
Malka D; Cervera P; Foulon S; Trarbach T; de la Fouchardière C; Boucher E; Fartoux L; Faivre S; Blanc JF; Viret F; Assenat E; Seufferlein T; Herrmann T; Grenier J; Hammel P; Dollinger M; André T; Hahn P; Heinemann V; Rousseau V; Ducreux M; Pignon JP; Wendum D; Rosmorduc O; Greten TF;
Lancet Oncol; 2014 Jul; 15(8):819-28. PubMed ID: 24852116
[TBL] [Abstract][Full Text] [Related]
13. Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice.
Zhang S; Song X; Cao D; Xu Z; Fan B; Che L; Hu J; Chen B; Dong M; Pilo MG; Cigliano A; Evert K; Ribback S; Dombrowski F; Pascale RM; Cossu A; Vidili G; Porcu A; Simile MM; Pes GM; Giannelli G; Gordan J; Wei L; Evert M; Cong W; Calvisi DF; Chen X
J Hepatol; 2017 Dec; 67(6):1194-1203. PubMed ID: 28733220
[TBL] [Abstract][Full Text] [Related]
14. Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study.
Shi GM; Huang XY; Wu D; Sun HC; Liang F; Ji Y; Chen Y; Yang GH; Lu JC; Meng XL; Wang XY; Sun L; Ge NL; Huang XW; Qiu SJ; Yang XR; Gao Q; He YF; Xu Y; Sun J; Ren ZG; Fan J; Zhou J
Signal Transduct Target Ther; 2023 Mar; 8(1):106. PubMed ID: 36928584
[TBL] [Abstract][Full Text] [Related]
15. [A Case of Combined Hepatocellular Carcinoma and Cholangiocarcinoma with Multidisciplinary Treatment Including Lenvatinib].
Furuya K; Ioka T; Shindo Y; Tokumitsu Y; Matsui H; Matsukuma S; Nakajima M; Yamada K; Watanabe Y; Tomochika S; Yoshida S; Iida M; Suzuki N; Takeda S; Nagano H
Gan To Kagaku Ryoho; 2021 Dec; 48(13):1694-1696. PubMed ID: 35046300
[TBL] [Abstract][Full Text] [Related]
16. Delayed response to maintenance therapy after first-line chemotherapy in metastatic intrahepatic cholangiocarcinoma: a case report.
Marciano R; Servetto A; Bianco C; Bianco R
J Med Case Rep; 2017 Sep; 11(1):273. PubMed ID: 28946921
[TBL] [Abstract][Full Text] [Related]
17. Reversible posterior leukoencephalopathy syndrome associated with concurrent bevacizumab, gemcitabine, and oxaliplatin for cholangiocarcinoma.
Chang Y; Mbeo G; Littman SJ
J Gastrointest Cancer; 2012 Sep; 43(3):505-7. PubMed ID: 21556724
[TBL] [Abstract][Full Text] [Related]
18. Locoregional Therapy Plus Systemic Chemotherapy in Unresectable Intrahepatic Cholangiocarcinoma.
Yang X; Pan J; Zhao H
JAMA Oncol; 2020 Jun; 6(6):935. PubMed ID: 32271359
[No Abstract] [Full Text] [Related]
19. Locoregional Therapy Plus Systemic Chemotherapy in Unresectable Intrahepatic Cholangiocarcinoma-Reply.
Cercek A; Jarnagin WR
JAMA Oncol; 2020 Jun; 6(6):935-936. PubMed ID: 32271367
[No Abstract] [Full Text] [Related]
20. Pathological complete response of liver metastases of cholangiocarcinoma using hepatic intra-arterial gemcitabine-oxaliplatin.
Bran DM; Fuks D; Lansier A; Gallois C; Karoui M; Taieb J; Lahlou W
Clin Res Hepatol Gastroenterol; 2022 Oct; 46(8):101920. PubMed ID: 35390538
[No Abstract] [Full Text] [Related]
[Next] [New Search]
